Study of the effect of the VEGF receptor blockade on the antiischemic activity of the compound GK-2 in a rat hind limb ischemia model

Earlier, in experiments in vitro and in vivo, it was shown that the TrkA receptor agonist compound GK-2, which was a low molecular weight NGF mimetic, had pronounced angiogenic and antiischemic activity. However, it remained unclear whether this activity was associated with the activation of VEGF-A, since, on the one hand, there are reports that NGF-mediated angiogenesis can be initiated by activating NGF of the vascular endothelial growth factor VEGF-A, and on the other hand, it is shown that a selective antagonist of Flk1 receptors specific for VEGF-A, compound SU-5416 does not affect the angiogenic effect of NGF. Purpose of the investigation. Study of the selective VEGF blockade effect on the antiischemic activity of the TrkA receptor agonist GK-2. Methods. Evaluation of the compound GK-2 antiischemic activity was assessed in model experiments simulating hind limb ischemia in rats. Results. It has been shown that against the background of blockade of VEGF-A binding with specific for it (VEGFR1 / Flt-1 / and VEGFR2 / KDR /) receptors, bevacizumab (2.5 mg / kg, i.p., every 3 days for 14 days) compound GK-2 (1 mg / kg, i.p., daily, for 14 days) realizes its antiischemic activity. Conclusion. The results of these experiments indicate that the selective blockade of VEGF does not significantly affect the anti-ischemic activity of the dipeptide NGF mimetic compound GK-2, which has the properties of a TrkA receptor agonist.

1. Donovan MJ, Miranda RC, Kraemer R et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol. 1995;147(2):309–324. https:// hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4884

2. Martinelli PM, Camargos ER, Azevedo AA et al. Cardiac NGF and GDNF expression during Trypanosoma cruzi infection in rats. Auton Neurosci. 2006;130(1-2):32–40. DOI: 10.1016/j.autneu.2006.05.004.

3. Asanome A, Kawabe J, Matsuki M, Kabara M, Hira Y, Bochimoto H, Yamauchi A, Aonuma T, Takehara N, Watanabe T, Hasebe N. Nerve growth factor stimulates regeneration of perivascular nerve, and induces the maturation of microvessels around the injured artery. Biochem Biophys Res Commun. 2014;443(1):150–155. DOI: 10.1016/j.bbrc.2013.11.070.

4. Wang J, He C, Zhou T, Huang Z, Zhou L, Liu X. NGF increases VEGF expression and promotes cell proliferation via ERK1/2 and AKT signaling in Müller cells. Mol Vis. 2016;22: 254–263.

5. Lazarovici P, Gazit A, Stanizewska I et al. Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothelium. 2006;13(1):51–59. DOI: 10.1080/10623320600669053.

6. Gudasheva TA, Antipova TA, Seredenin SB. Novel low-molecular-weight mimetics of the nerve growth factor Dokl Biochem Biophys. 2010;434(1): 262–265. (In Russ). DOI:10.1134/S160767291005011X.

7. Ishida J, Onishi M, Kurozumi K, Ichikawa T, Fujii K, Shimazu Y, Oka T, Date I. Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol. 2014;7(2):292–302.e1. DOI: 10.1016/j.tranon.2014.02.016.

8. Soysal D, Kızıldağ S, Saatlı B, Posacı C, Soysal S, Koyuncuoğlu M, Doğan Ö. A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model. Balkan J Med Genet. 2015;17(2):73–80. DOI: 10.2478/bjmg-2014-0077.